Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.Cancer.(2018).
Comparative Outcomes of Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Acute Myeloid Leukemia with Prior Solid Tumor: a report from the ALWP of the EBMT.Am J Hematol.(2018).
[Harmonization of data coding in post-transplant follow-up - "GVHD, complications and additional treatments": Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].Bull Cancer.(2018).
HLA mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis.Biol Blood Marrow Transplant.(2018).
Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party Eu.Am J Hematol.(2018).
Are hypomethylating agents replacing induction-type chemotherapy prior to allogeneic stem cell transplantation in patients with myelodysplastic syndrome?.Biol Blood Marrow Transplant.(2014).
Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT.Haematologica.(2014).